We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byAiden Patton
Modified over 3 years ago
R&D Financing by the Bill & Melinda Gates FoundationPRESENTED BY Neil McDonnell, Pharm.D. January 12, 2009 WHO Expert Working Group on R&D Financing
Gates Foundation MissionTo ensure that life-saving advances in health are developed & shared with those who need them the most. (Photo, chart, or graph here) © 2009 Bill & Melinda Gates Foundation | ‹2›
How We Prioritize Our WorkGreatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | ‹3›
DALYs by Cause, Low Income CountriesNon-Foundation Priorities: 43% Foundation Priorities: 57% © 2009 Bill & Melinda Gates Foundation | ‹4›
How We Prioritize Our WorkGreatest burden The areas that cause widespread illness and death: infectious diseases, undernutrition, and reproductive maternal, neonatal, and child health Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Benefit the most people Prevention has the greatest impact – focus on vaccines and other prevention strategies, micronutrient deficiencies Be willing to take risks Innovation requires accepting risks © 2009 Bill & Melinda Gates Foundation | ‹5›
Foundation Support for Discovery, Development, and DeliveryGlobal Health Impact Appropriate Uptake and Use © 2009 Bill & Melinda Gates Foundation | ‹6›
Gates Foundation Support for Drugs and Vaccines in Late-Stage Preclinical or Clinical DevelopmentProduct Class Candidates HIV (Vaccines) 13 HIV (Non-Vaccine Prevention) 9 TB (Vaccines) 6 TB (drugs) 2 Malaria (vaccines) 10 Malaria (drugs) Pneumonia (vaccines) 5 Diarrhea (vaccines) 11 Diarrhea (drugs) 1 Dengue Fever Visceral Leishmaniasis 3 Human African Trypanosomiasis Hookworm Japanese Encephalitis Human Papillomavirus Product/Platform Candidates 4 Total 77 © 2009 Bill & Melinda Gates Foundation | ‹7›
Product Development Partnerships Supported by the Gates FoundationDiarrhea International Vaccine Institute Enteric Vaccine Initiative Advancing Rotavirus Vaccine Development HIV/AIDS International AIDS Vaccine Initiative International Partnership for Microbicides Malaria Medicines for Malaria Venture Malaria Vaccine Initiative NTD Dengue: Pediatric Dengue Vaccine Initiative Hookworm: Human Hookworm Vaccine Initiative Leishmaniasis: Infectious Disease Research Institute Trypanosomiasis: UNC Consortium for Parasitic Drug Development Multiple: Drugs for Neglected Diseases Initiative Respiratory Infection Influenza Vaccine Development Program Meningitis Vaccine Project Pneumococcal Vaccine Development Program TB Aeras Global TB Vaccine Foundation Global Alliance for TB Drug Development Cross-Cutting Foundation for Innovative New Diagnostics Innovative Vector Control Consortium Institute for One World Health © 2009 Bill & Melinda Gates Foundation | ‹8›
Global Health Program Payout© 2008 Bill & Melinda Gates Foundation
The Need for R&D in Global HealthGuaranteed obsolescence in infectious diseases We need for newer, better methods of prevention Many disease for which no effective treatment or prevention is available Innovation is required to meet these challenges Financing innovation requires a willingness to make extremely risky investments © 2008 Bill & Melinda Gates Foundation
Providing Access to Medicines and Vaccines for the Poor – Focus on R & DGovernments Support for basic research Support innovative finance mechanisms designed to stimulate R&D Support for funds such as the Global Fund, GAVI, UNITAID, etc. Industry Research, development, and manufacturing to addresses global disease burden and neglected diseases Access Plans © 2008 Bill & Melinda Gates Foundation
Providing Access to Medicines and Vaccines for the Poor – Focus on R & DFoundations Work in defined niches Support innovation and development of new health solutions Operating at the interface between governments, the private sector, and other interested parties De-risking subsequent investments by the public and private sectors © 2008 Bill & Melinda Gates Foundation
Many players to incentivize in R&D, final common pathway through industryPharma Biotech Govern-ment Lab Academic Lab Academic Lab ResearchInstitute ResearchInstitute Discovery Development Product Approval Introduction Govern-ment Lab Pharma Biotech Govern-ment Lab Biotech Company Pharma Biotech Company Pharma Pharma Biotech © 2008 Bill & Melinda Gates Foundation
Stimulating Global Health R&DWe need incentives for governments, foundations, and a broad cross section of industries to participate in the R&D effort We need to identify novel mechanisms to fund global health R&D and new policies that encourage more R&D. We have to be willing to take risks © 2008 Bill & Melinda Gates Foundation
11 MALARIA STRATEGY Presentation at Roll Back Malaria information session David Brandling-Bennett and Gabrielle Fitzgerald November 10, 2008.
Global Health Program Guiding Principles April 2002.
Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.
WHO Expert Working Group on R&D and Financing January 2009 G-FINDER: Global Funding of Innovation for Neglected Diseases.
MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.
Sources of Support and What They Mean to the Field Dr. Duff Gillespie June 15 th, 2002 Africa SOTA, Nairobi.
Designing Strategies for Neglected Disease Research: What Innovations Do We Need? Julia Walsh MD MSc UCB School of Public Health
Global Forum for Health Research Mumbai, September 12 to Rob Ridley Director, TDR Sustaining Priority Research for Neglected Tropical Diseases.
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation.
Chapter Sixteen Science, Technology, and Global Health.
Working Together to Improve Global Health
Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.
RESEARCH FOR HEALTH RESEARCH AGENDA Gilbert Kokwaro, PhD Consortium for National Health Research.
What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010.
Global Alliance for Vaccines and Immunization. n An Alliance u Traditional and new partners u Public and private sector n Partners have in common: u Situation.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni TannaMarjolein.
Advance Market Commitments for Vaccines Carlo Monticelli International Financial Relations Ministero dell’Economia e delle Finanze.
UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.
UNITAID Innovative Financing Mechanism Denis Broun Executive Director.
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10,
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
COUNTRY ACTION: SUSTAINABLE INVESTMENT STOP TB PARTNERSHIP FORUM STOP TB PARTNERSHIP FORUM 24TH-26TH MARCH TH-26TH MARCH 2004 BY BY MRS NENADI USMAN.
Nutrition/HIV – new developments Increased Evidence Base – e.g. micronutrient supplements, RUTF High Profile Meetings – Durban, Blantyre. Others planned.
Center for Global Health R&D Policy Assessment Presentation to the WHO CEWG 6 April 2011 Kimberly Manno Reott, Project Director.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Gaps from the Perspective of NGOs/ Foundations/PDPs IoM Workshop: International Regulatory Harmonization Amid Globalization of Biomedical Research & Medical.
Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane.
Polio Eradication Although the number of endemic countries is at an all-time low in 2002, the actual number of cases was approximately four times higher.
Sustainability: The R&D Pipeline for Neglected Disease Vaccines Elizabeth L. Ponder, PhD May 4, 2011 Global Vaccines 202X: Access, Equity, Ethics 2-4 May.
Bi-State TB Elimination April 10, 2014 Anna Frye Michelle Goodyear Tuberculosis: Recent Trends and Relevant Research.
Research Leaders: Meeting the challenge Mark Walport 19 November 2008.
Health Economics. Outline Health Economics Do Health and Economics go well together? Health Economics: An interesting job Who is hiring health economists...
AusAID’s approach to health in developing countries
OVERVIEW OF MACROECONOMIC & HEALTH KEY POINTS FROM THE OCTOBER 2003 GLOBAL CONSULTATION Briefing for Permanent Mission Representatives.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD: a public health approach to innovation Hans V. Hogerzeil Director, Medicines Policy and Standards WHO, Geneva.
Deadly Imbalance: Social vs Medical Value of Preventative Vaccines Donald P. Francis, MD, DSc Global Solutions for Infectious Diseases Brisbane, CA, USA.
Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
World Health Organization Information, Evidence and Research The Road to Bamako Tim Evans Assistant Director General, WHO Scaling Up Research and Learning.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
WASH Cluster – Emergency Training D D1 1 WASH Related Diseases Session 1 The Environmental Burden of Disease.
The Pilot Advance Market Commitment for Vaccines Tania Cernuschi Senior Manager, AMC GAVI Alliance Marketplace on Innovative.
Global Fund Work on HIV/SRH Linkages 09 March 2015 Olga Bornemisza New York, USA IAWG Meeting on HIV/SRH Linkages.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
© 2017 SlidePlayer.com Inc. All rights reserved.